Skip to content
Participate in our active studies
Subscribe to our Mailing List
AB Science
Masitinib and AB8939 – Two compounds with breakthrough mechanism of action
Home
Company
Corporate Overview
Executive Commitee
Scientific Committee
Values
Science
Overview
Masitinib in neurodegenerative disorders
Masitinib in inflammatory diseases
Masitinib in oncology
Masitinib in viral diseases
AB8939 in oncology
Publications
Pipeline
Pipeline Overview
Masitinib
Multiple Sclerosis
Amyotrophic Lateral Sclerosis
Alzheimer’s Disease
Indolent Systemic Mastocytosis
Mast Cell Activation Syndrome
Severe Asthma
Prostate Cancer
Pancreatic Cancer
COVID-19
AB8939
News and Media
Press releases
In the Media
Webconference replay
Investors
Why invest in AB Science
Investor Kit
Regulated information
Annual reports
Half-year reports
Social and environmental responsabilities
Shareholders General Meeting
Outstanding shares and voting rights
Regulated agreements
Stock Information
General Information
Analyst Coverage
Financial Calendar
Events
Masivet®
About Masivet®
Medical information and Pharmacovigilance
Careers
Contact
Search:
Home
Company
Corporate Overview
Executive Commitee
Scientific Committee
Values
Science
Overview
Masitinib in neurodegenerative disorders
Masitinib in inflammatory diseases
Masitinib in oncology
Masitinib in viral diseases
AB8939 in oncology
Publications
Pipeline
Pipeline Overview
Masitinib
Multiple Sclerosis
Amyotrophic Lateral Sclerosis
Alzheimer’s Disease
Indolent Systemic Mastocytosis
Mast Cell Activation Syndrome
Severe Asthma
Prostate Cancer
Pancreatic Cancer
COVID-19
AB8939
News and Media
Press releases
In the Media
Webconference replay
Investors
Why invest in AB Science
Investor Kit
Regulated information
Annual reports
Half-year reports
Social and environmental responsabilities
Shareholders General Meeting
Outstanding shares and voting rights
Regulated agreements
Stock Information
General Information
Analyst Coverage
Financial Calendar
Events
Masivet®
About Masivet®
Medical information and Pharmacovigilance
Careers
Contact
Annual reports
You are here:
Home
Investors
Regulated information
Annual reports
2023
Annual Financial Report – PDF Format
Annual financial report for the year ended 31st December 2023
Annual Financial Report – ESEF Format
Annual financial report for the year ended 31st December 2023
2022
Annual Financial Report – PDF Format
Annual financial report for the year ended 31st December 2022
Annual Financial Report – ESEF Format
Annual financial report for the year ended 31st December 2022
2021
Annual Financial Report
Annual financial report for the year ended 31st December 2021
2020
Annual Financial Report
Annual financial report for the year ended 31st December 2020
2019
Annual Financial Report
Annual financial report for the year ended 31st December 2019
2018
Annual Financial Report
Annual financial report for the year ended 31st December 2018
2017
Annual Financial Report
Annual financial report for the year ended 31st December 2017
2016
Annual Financial Report
Annual financial report for the year ended 31st December 2016
2015
Annual Financial Report
Annual financial report for the year ended 31st December 2015
2014
Annual Financial Report
Annual financial report for the year ended 31st December 2014
2013
Annual Financial Report
Annual financial report for the year ended 31st December 2013
2012
Annual Financial Report
Annual financial report for the year ended 31st December 2012
2011
Annual Financial Report
Annual financial report for the year ended 31st December 2011
2010
Annual Financial Report
Annual financial report for the year ended 31st December 2010
Go to Top
